Therapeutic Intervention Feasible for Preventing Rheumatoid Arthritis in Patients at Risk
FRIDAY, Feb. 23, 2024 -- Therapeutic intervention with abatacept is feasible for patients at risk for rheumatoid arthritis, according to a study published online Feb. 13 in The Lancet. Andrew P. Cope, M.D., from King ' s College London, and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 23, 2024 Category: Pharmaceuticals Source Type: news

Another Study Backs Treatment for Preclinical Rheumatoid Arthritis
(MedPage Today) -- Inflammatory markers were reduced in patients with persistent joint pain and other markers for incipient rheumatoid arthritis (RA), as was progression to formal RA diagnosis, after a 6-month course of abatacept (Orencia) in a... (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - February 16, 2024 Category: Rheumatology Source Type: news

Clinical trial shows rheumatoid arthritis drug could prevent disease
A drug used to treat rheumatoid arthritis could also prevent the disease in individuals deemed to be at risk. Results from a Phase 2b clinical trial, published in The Lancet by researchers led by King's College London, provides hope for arthritis sufferers after it was shown that the biologic drug abatacept reduces progression to this agonising chronic inflammatory disease. (Source: World Pharma News)
Source: World Pharma News - February 14, 2024 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Abatacept Slows Progression to RA, Phase 2b Trial Finds Abatacept Slows Progression to RA, Phase 2b Trial Finds
The study was conducted at 28 sites in the United Kingdom and three in the Netherlands.MDedge News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - November 28, 2023 Category: Drugs & Pharmacology Tags: Rheumatology News Source Type: news

FDA Approves Abatacept for Pediatric Patients With Psoriatic Arthritis FDA Approves Abatacept for Pediatric Patients With Psoriatic Arthritis
As many as 5% of pediatric patients with juvenile idiopathic arthritis are estimated to have juvenile PsA.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 31, 2023 Category: Allergy & Immunology Tags: Rheumatology News Source Type: news

Abatacept, Certolizumab: Best Biologics in Early RA? Abatacept, Certolizumab: Best Biologics in Early RA?
The study was the first head-to-head comparison of multiple biologics plus methotrexate vs active conventional DMARDs plus steroid bridging for the management of early rheumatoid arthritis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 12, 2023 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Safety Outcomes in RA Patients Treated With Abatacept Safety Outcomes in RA Patients Treated With Abatacept
These results add to the current evidence on the safety of the biologic DMARD abatacept for the treatment of rheumatoid arthritis.Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 15, 2023 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Immunomodulators Flop for COVID-19 Pneumonia Outcomes
(MedPage Today) -- Immunomodulators abatacept (Orencia), cenicriviroc, and infliximab (Remicade) all failed to improve time to recovery for patients hospitalized with COVID-19 pneumonia in the randomized, double-masked ACTIV-1 platform trial.... (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - July 12, 2023 Category: Infectious Diseases Source Type: news

Trial Shows RA Can Be Stopped at Preclinical Stage
(MedPage Today) -- MILAN -- One year of treatment with abatacept (Orencia) kept "preclinical" rheumatoid arthritis (RA) from becoming clinical in most patients showing signs of imminent onset, a researcher reported here. In a phase IIb randomized... (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - June 1, 2023 Category: Primary Care Source Type: news

New Tx Approach for Immunotherapy-Induced Myocarditis New Tx Approach for Immunotherapy-Induced Myocarditis
A novel combination of high-dose abatacept, ruxolitinib, and mechanical ventilation markedly improved immunotherapy-induced myocarditis survival over current guideline-recommended treatment.Medscape Medical News (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - March 1, 2023 Category: Intensive Care Tags: Hematology-Oncology News Source Type: news

Anti-Inflammatory Agents May Have Role in COVID-19 Pneumonia
(MedPage Today) -- WASHINGTON -- Use of the anti-inflammatory agents infliximab (Remicade) and abatacept (Orencia) added to standard of care showed a hint of improvement in outcomes for patients hospitalized with COVID-19 pneumonia, according... (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - October 25, 2022 Category: Infectious Diseases Source Type: news

Results of Novel Clinical Study of Guselkumab and Golimumab Combination Therapy Show Adults with Moderately to Severely Active Ulcerative Colitis Maintained Higher Rates of Clinical, Histologic, and Endoscopic Remission at Week 38
SPRING HOUSE, PENNSYLVANIA, October 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from an ongoing analysis of a Phase 2a clinical trial showing adults with moderately to severely active ulcerative colitis (UC) who received 12 weeks of combination induction therapy with guselkumab and golimumab, followed by a transition to guselkumab alone for maintenance, achieved a clinical remission ratea (based on the modified Mayo score [mMayo])b at week 38 of 47.9 percent, a higher rate than induction and maintenance treatment with either guselkumab alone (31.0 percent) or golimumab al...
Source: Johnson and Johnson - October 10, 2022 Category: Pharmaceuticals Source Type: news

Possible Sex Differences Found in Early RA Drug Responses Possible Sex Differences Found in Early RA Drug Responses
In a rigorous analysis of sex differences in response to RA treatments, men had higher rates of remission than did women taking certolizumab pegol, abatacept, or conventional therapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 13, 2022 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Researchers take aim at cancer drugs ’ toxic side effects
The patient was a success story, his advanced melanoma erased by a popular new cancer treatment. Known as immune checkpoint inhibitors, the drugs coax the immune system to seek and destroy cancer cells—and in this case, they “worked beautifully,” says Kerry Reynolds, an oncologist at Massachusetts General Hospital (MGH) who helped care for the man. But about a month after an infusion, without a melanoma cell detectable in his body, the 64-year-old was admitted to the hospital, gravely ill. The drugs were sending his immune system into overdrive, wreaking havoc on his colon and nervous system. Doctors strug...
Source: ScienceNOW - August 31, 2022 Category: Science Source Type: news

A Newly Published Network Meta-Analysis (NMA) Found TREMFYA ® (guselkumab) Ranked Highest for Overall Level of Skin Clearance and Provided Positive Joint Efficacy Among Active Psoriatic Arthritis (PsA) Therapies
Conclusions (i.e., comparable) are based on an overlap of pairwise 95 percent credible intervals.1c. PASI 90 is defined as at least 90 percent improvement from baseline in the PASI score. The PASI score grades the amount of surface area on each body region that is covered by PsO plaques and the severity of plaques for their redness, thickness, and scaliness.13 PASI 90 was not a controlled endpoint in DISCOVER-1 or -2.8,9d. TREMFYA q4w dosing is not currently FDA-approved.2e. The PsA-modified vdH-S score combines erosion and joint space narrowing scores derived from radiographs of joints in body regions impacted by PsA.14 T...
Source: Johnson and Johnson - January 26, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news